SIBN Earnings Prediction
The chart below shows how SIBN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SIBN sees a +1.69% change in stock price 10 days leading up to the earnings, and a -3.62% change 10 days following the report. On the earnings day itself, the stock moves by -0.54%. This data can give you a slight idea of what to expect for the next quarter's release.
SIBN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
49.00M
26.10%
21.47%
Gross Margin
79.13%
7.22%
0.05%
Operating Margin
-11.21%
-65.16%
-40.75%
Net Margin
-9.17%
-67.55%
-43.74%
EPS
-0.11
-59.26%
-31.25%
No Data Available
SIBN Earnings Analysis
SI-BONE Inc Corporation (SIBN.O) Earnings Conference Call
Positive
Earnings Surprise Report: SI-BONE, Inc. beats earnings expectations with reported EPS of $-0.11, exceeding expectations of $-0.16.
Record Revenue Achievement: The company achieved a record $49 million in worldwide revenue for Q4 2024, representing growth exceeding 26%.
U.S. Revenue Surge: U.S. revenue increased by 28% to $46.9 million, driven by strong demand from nearly 1,400 active physicians.
Granite 9.5 Market Acceptance: The adoption of Granite 9.5 has outpaced previous product launches, indicating strong market acceptance.
TNT Product Adoption Success: The newly launched TNT product has exceeded expectations in terms of adoption, suggesting a positive market response.
Positive EBITDA Outlook: SI-BONE delivered positive adjusted EBITDA in Q4 2024, with expectations for continued profitability in 2025.
Sales Force Expansion Strategy: The company plans to expand its direct sales force to capitalize on strong procedure demand, indicating growth potential.
Physician Growth Rate: The number of active physicians grew by 23% year-over-year, with nearly 1,400 active physicians performing procedures in Q4 2024.
Physician Training Revenue Growth: Revenue from physicians trained as residents and fellows grew by 70%, highlighting the effectiveness of training programs.
Transitional Payment Status: Granite 9.5 received transitional pass-through payment status, enhancing its reimbursement profile and clinical value.
Breakthrough Device Designation: The company has been awarded breakthrough device designation for a new implant system, positioning it for future growth.
Positive Free Cash Flow: SI-BONE expects to achieve positive free cash flow as it continues to improve its profitability and liquidity position.
Negative
Net Loss Improvement: The company reported a net loss of $4.5 million for Q4 2024, despite an improvement of nearly 60% compared to the previous year, indicating ongoing financial challenges.
Global Market Penetration Issues: International revenue was only $2.1 million in Q4 2024, which is significantly lower than U.S. revenue, highlighting a lack of global market penetration.
Rising Operating Expenses: Operating expenses grew by 8% to $44.3 million in Q4 2024, which could indicate rising costs that may impact future profitability.
DOJ Investigation Risks: The company is facing a Department of Justice investigation, which could pose risks to its operations and reputation, although no material updates were provided during the call.
Net Loss Despite EBITDA: Despite positive adjusted EBITDA in Q4 2024, the company still reported a net loss for the full year, indicating that profitability remains a challenge.
Conservative Revenue Growth Outlook: The guidance for 2025 indicates expected revenue growth of only 16% to 17%, which may be seen as conservative given the company's previous growth rates.
SIBN FAQs
How does SIBN typically perform around its earnings report dates?
Is SI-BONE Inc (SIBN) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SIBN Earning Call Sentiment
SI-BONE, Inc. (NASDAQ:SIBN) Q4 2024 Earnings Call Transcript
SIBN.O
-3.95%Positive
The earnings call reveals strong financial performance with significant revenue growth and improved profitability. Despite some concerns in the Q&A about lower guidance and competitive landscape, the company's leadership in SI joint fusion and new product launches are positive indicators. The absence of shareholder return announcements is a minor negative, but the overall financial health, growth in active physicians, and improved EBITDA suggest a positive stock price movement.
